1.A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL - Full Text View - ClinicalTrials.gov
2.Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study | Blood Advances | American Society of Hematology (ashpublications.org)